중독·부작용 | Cases and Studies of Addiction & Disorder in Lottery & Gambling | 中毒 & 疾病
- date : 2015-05-20 01:10|hit : 2269
-
- Article] Individual Differences in Nucleus Accumbens Dopamine Receptors Predict Development of Addiction-Like Behavior: A Computational Approach
-
DocNo of ILP: 2535
Doc. Type: Article
Title: Individual Differences in Nucleus Accumbens Dopamine Receptors Predict Development of Addiction-Like Behavior: A Computational Approach
Authors: Piray, P; Keramati, MM; Dezfouli, A; Lucas, C; Mokri, A
Full Name of Authors: Piray, Payam; Keramati, Mohammad Mahdi; Dezfouli, Amir; Lucas, Caro; Mokri, Azarakhsh
Keywords by Author:
Keywords Plus: VENTRAL TEGMENTAL AREA; POSITRON-EMISSION-TOMOGRAPHY; SELF-ADMINISTER COCAINE; TRIAL PLACE PREFERENCE; BETA-GAMMA-SUBUNITS; DORSAL STRIATUM; DRUG-ADDICTION; OLFACTORY TUBERCLE; NEURONS ENCODE; BASAL GANGLIA
Abstract: Clinical and experimental observations show individual differences in the development of addiction. Increasing evidence supports the hypothesis that dopamine receptor availability in the nucleus accumbens (NAc) predisposes drug reinforcement. Here, modeling striatal-midbrain dopaminergic circuit, we propose a reinforcement learning model for addiction based on the actor-critic model of striatum. Modeling dopamine receptors in the NAc as modulators of learning rate for appetitive-but not aversive-stimuli in the critic-but not the actor-we define vulnerability to addiction as a relatively lower learning rate for the appetitive stimuli, compared to aversive stimuli, in the critic. We hypothesize that an imbalance in this learning parameter used by appetitive and aversive learning systems can result in addiction. We elucidate that the interaction between the degree of individual vulnerability and the duration of exposure to drug has two progressive consequences: deterioration of the imbalance and establishment of an abnormal habitual response in the actor. Using computational language, the proposed model describes how development of compulsive behavior can be a function of both degree of drug exposure and individual vulnerability. Moreover, the model describes how involvement of the dorsal striatum in addiction can be augmented progressively. The model also interprets other forms of addiction, such as obesity and pathological gambling, in a common mechanism with drug addiction. Finally, the model provides an answer for the question of why behavioral addictions are triggered in Parkinson's disease patients by D2 dopamine agonist treatments.
Cate of OECD: Computer and information sciences
Year of Publication: 2010
Business Area: gamble
Detail Business: gamble
Country: USA
Study Area:
Name of Journal: NEURAL COMPUTATION
Language: English
Country of Authors: [Piray, Payam; Dezfouli, Amir; Lucas, Caro] Univ Tehran, Sch Elect & Comp Engn, Control & Intelligent Proc Ctr Excellence, Tehran, Iran; [Keramati, Mohammad Mahdi] Sharif Univ Technol, Sch Management & Econ, Tehran, Iran; [Mokri, Azarakhsh] Univ Tehran Med Sci, Roozbeh Hosp, Dept Psychiat, Tehran, Iran; [Mokri, Azarakhsh] Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Dept Clin Sci, Tehran, Iran
Press Adress: Piray, P (reprint author), Univ Tehran, Sch Elect & Comp Engn, Control & Intelligent Proc Ctr Excellence, Tehran, Iran.
Email Address: piray@ut.ac.ir; keramati_mm@alum.sharif.edu; a.dezfouli@ut.ac.ir; lucas@ut.ac.ir; mokriazr@sina.tums.ac.ir
Citaion:
Funding:
Lists of Citation: Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298; Ahmed SH, 2004, SCIENCE, V306, P1901, DOI 10.1126/science.1107071; Ahmed SH, 2005, PSYCHOPHARMACOLOGY, V180, P473, DOI 10.1007/s00213-005-2180-z; Ahmed SH, 2008, BEHAV BRAIN SCI, V31, P437, DOI 10.1017/S0140525X08004731; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anthony James C., 1994, Experimental and Clinical Psychopharmacology, V2, P244, DOI 10.1037/1064-1297.2.3.244; Atallah HE, 2007, NAT NEUROSCI, V10, P126, DOI 10.1038/nn1817; Bachtell RK, 2005, PSYCHOPHARMACOLOGY, V183, P41, DOI 10.1007/s00213-005-0133-1; Balleine BW, 2007, J NEUROSCI, V27, P8161, DOI 10.1523/JNEUROSCI.1554-07.2007; Bayer HM, 2005, NEURON, V47, P129, DOI 10.1016/j.neuron.2005.05.020; Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136; Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Beveridge TJR, 2009, NEUROPSYCHOPHARMACOL, V34, P1162, DOI 10.1038/npp.2008.135; Bolanos CA, 2003, J NEUROSCI, V23, P7569; BRISCHOUX F, 2009, NATL ACAD SCI UNITED, V106, P4894; Caine SB, 1999, J PHARMACOL EXP THER, V291, P353; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; Carelli RM, 2002, PHYSIOL BEHAV, V76, P379, DOI 10.1016/S0031-9384(02)00760-6; CARLEZON WA, 1995, PSYCHOPHARMACOLOGY, V122, P194, DOI 10.1007/BF02246095; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; CARLEZON WA, 2000, J NEUROSCI, V20, P1; Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995; CORRIGALL WA, 1991, PHARMACOL BIOCHEM BE, V39, P799, DOI 10.1016/0091-3057(91)90168-2; Dagher A, 2009, NEURON, V61, P502, DOI 10.1016/j.neuron.2009.01.031; DALLEY JW, 2007, SCIENCE, V1270, pD2; Daw ND, 2002, NEURAL NETWORKS, V15, P603, DOI 10.1016/S0893-6080(02)00052-7; Daw ND, 2005, NAT NEUROSCI, V8, P1704, DOI 10.1038/nn1560; DAYAN P, 2009, PHARMACOPSYCHIATRY, V1, pS56; Dayan P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040004; DE WITH, 1986, DRUG ALCOHOL DEPEN, V16, P341; Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020; Dezfouli A, 2009, NEURAL COMPUT, V21, P2869, DOI 10.1162/neco.2009.10-08-882; Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032; Edwards S, 2007, NEUROPSYCHOPHARMACOL, V32, P354, DOI 10.1038/sj.npp.1301062; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089; Fenu S, 2006, PSYCHOPHARMACOLOGY, V187, P143, DOI 10.1007/s00213-006-0415-2; Ford CP, 2006, J NEUROSCI, V26, P2788, DOI 10.1523/JNEUROSCI.4331-05.2006; Frank MJ, 2007, P NATL ACAD SCI USA, V104, P16311, DOI 10.1073/pnas.0706111104; Frank MJ, 2004, SCIENCE, V306, P1940, DOI 10.1126/science.1102941; Frank MJ, 2009, NAT NEUROSCI, V12, P1062, DOI 10.1038/nn.2342; Frank MJ, 2009, J MOL CELL BIOL, V1, P15, DOI 10.1093/jmcb/mjp010; Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789; Goldstein RZ, 2007, AM J PSYCHIAT, V164, P43, DOI 10.1176/appi.ajp.164.1.43; Goto Y, 2005, NAT NEUROSCI, V8, P805, DOI 10.1038/nn1471; Gutkin BS, 2006, P NATL ACAD SCI USA, V103, P1106, DOI 10.1073/pnas.0510220103; Haber S. N., 2009, NEUROPSYCHOPHARMACOL, V35, P4, DOI [10.1038/npp.2009.129, DOI 10.1038/NPP.2009.129]; Haber SN, 2000, J NEUROSCI, V20, P2369; Hazy TE, 2007, PHILOS T R SOC B, V362, P1601, DOI 10.1098/rstb.2007.2055; Hopf FW, 2003, J NEUROSCI, V23, P5079; Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414; HYMAN SE, 2006, ANN REV OF NEUROSCIE, V565, P598; Ikemoto S, 2007, BRAIN RES REV, V56, P27, DOI 10.1016/j.brainresrev.2007.05.004; Ikemoto S, 1997, J NEUROSCI, V17, P8580; Ikemoto S, 2002, J NEUROSCI, V22, P9895; Ikemoto S, 2003, J NEUROSCI, V23, P9305; Ikemoto S, 2005, J NEUROSCI, V25, P5061, DOI 10.1523/JNEUROSCI.0892-05.2005; Ikemoto S, 1998, PHARMACOL BIOCHEM BE, V61, P87, DOI 10.1016/S0091-3057(98)00086-0; Inoue Y, 2007, J PHARMACOL EXP THER, V322, P23, DOI 10.1124/jpet.107.120675; Ito M, 2009, J NEUROSCI, V29, P9861, DOI 10.1523/JNEUROSCI.6157-08.2009; Ito R, 2002, J NEUROSCI, V22, P6247; Janak PH, 2004, BEHAV BRAIN RES, V154, P125, DOI 10.1016/j.bbr.2004.02.003; Jentsch JD, 2002, NEUROPSYCHOPHARMACOL, V26, P183, DOI 10.1016/S0893-133X(01)00355-4; Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515; Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564; Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234; Kim H, 2009, J NEUROSCI, V29, P14701, DOI 10.1523/JNEUROSCI.2728-09.2009; Kim YB, 2007, J NEUROPHYSIOL, V98, P3548, DOI 10.1152/jn.00310.2007; Klein TA, 2007, SCIENCE, V318, P1642, DOI 10.1126/science.1145044; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Laruelle M, 1997, NEUROPSYCHOPHARMACOL, V17, P162; Lau B, 2008, NEURON, V58, P451, DOI 10.1016/j.neuron.2008.02.021; Lauwereyns J, 2002, NATURE, V418, P413, DOI 10.1038/nature00892; Mach RH, 1997, PHARMACOL BIOCHEM BE, V57, P477, DOI 10.1016/S0091-3057(96)00449-2; Mameli M, 2009, NAT NEUROSCI, V12, P1036, DOI 10.1038/nn.2367; Martinez D, 2009, NEUROPSYCHOPHARMACOL, V34, P1774, DOI 10.1038/npp.2008.235; Matsumoto M, 2009, NATURE, V459, P837, DOI 10.1038/nature08028; McClure SM, 2003, TRENDS NEUROSCI, V26, P423, DOI 10.1016/S0166-2236(03)00177-2; Montague PR, 1996, J NEUROSCI, V16, P1936; Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015; Moore RJ, 1998, SYNAPSE, V28, P1; Morgan M, 2002, QUALITATIVE RES, V2, P5, DOI DOI 10.1177/; Morris G, 2006, NAT NEUROSCI, V9, P1057, DOI 10.1038/nn1743; Moustafa AA, 2008, J NEUROSCI, V28, P12294, DOI 10.1523/JNEUROSCI.3116-08.2008; Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737; Nader MA, 2008, PHILOS T R SOC B, V363, P3223, DOI 10.1098/rstb.2008.0092; Nader MA, 2002, NEUROPSYCHOPHARMACOL, V27, P35, DOI 10.1016/S0893-133X(01)00427-4; Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006; Nicola SM, 2007, PSYCHOPHARMACOLOGY, V191, P521, DOI 10.1007/s00213-006-0510-4; Noble EP, 2003, AM J MED GENET B, V116B, P103, DOI 10.1002/ajmg.b.10005; O'Brien C. P., 1986, BEHAV ANAL DRUG DEPE, P329; O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285; Olson VG, 2005, J NEUROSCI, V25, P5553, DOI 10.1523/JNEUROSCI.0345-05.2005; Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937; Pasquereau B, 2007, J NEUROSCI, V27, P1176, DOI 10.1523/JNEUROSCI.3745-06.2007; Peterson DA, 2009, NEUROSCIENCE, V163, P1092, DOI 10.1016/j.neuroscience.2009.07.033; Pezze MA, 2007, NEUROPSYCHOPHARMACOL, V32, P273, DOI 10.1038/sj.npp.1301073; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; Porrino LJ, 2004, NEUROSCI BIOBEHAV R, V27, P813, DOI 10.1016/j.neubiorev.2003.11.013; Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004; Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100; Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X; Redish AD, 2007, PSYCHOL REV, V114, P784, DOI 10.1037/0033-295X.114.3.784; Redish AD, 2007, ANN NY ACAD SCI, V1104, P324, DOI 10.1196/annals.1390.014; Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rodd ZA, 2004, J NEUROSCI, V24, P1050, DOI 10.1523/JNEUROSCI.1319-03.2004; Rodd ZA, 2005, NEUROPSYCHOPHARMACOL, V30, P330, DOI 10.1038/sj.npp.1300561; Rodd-Henricks ZA, 2002, J PHARMACOL EXP THER, V303, P1216, DOI 10.1124/jpet.102.038950; Roesch MR, 2007, NAT NEUROSCI, V10, P1615, DOI 10.1038/nn2013; Roesch MR, 2009, J NEUROSCI, V29, P13365, DOI 10.1523/JNEUROSCI.2572-09.2009; Roesch MR, 2007, J NEUROSCI, V27, P245, DOI 10.1523/JNEUROSCI.4080-06.2007; Samejima K, 2005, SCIENCE, V310, P1337, DOI 10.1126/science.1115270; Schoenbaum G, 2009, NAT REV NEUROSCI, V10, P885, DOI 10.1038/nrn2753; Schoenbaum G, 2004, EUR J NEUROSCI, V19, P1997, DOI 10.1111/j.1460.9568.2004.03274.x; Schoenbaum G, 2005, CEREB CORTEX, V15, P1162, DOI 10.1093/cercor/bhh216; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Self DW, 2004, NEUROPHARMACOLOGY, V47, P242, DOI 10.1016/j.neuropharm.2004.07.005; Sellings LHL, 2006, NEUROSCIENCE, V141, P1457, DOI 10.1016/j.neuroscience.2006.04.040; Sellings LHL, 2003, J NEUROSCI, V23, P6295; Sellings LHL, 2006, J PHARMACOL EXP THER, V317, P1178, DOI 10.1124/jpet.105.100339; Shin R, 2008, PSYCHOPHARMACOLOGY, V198, P261, DOI 10.1007/s00213-008-1131-x; Spina L, 2006, PSYCHOPHARMACOLOGY, V184, P447, DOI 10.1007/s00213-005-0211-4; Steeves TDL, 2009, BRAIN, V132, P1376, DOI 10.1093/brain/awp054; Sutton R., 1998, REINFORCEMENT LEARNI; Taha SA, 2005, J NEUROSCI, V25, P1193, DOI 10.1523/JNEUROSCI.3975-04.2005; Takahashi Yuji, 2007, Front Integr Neurosci, V1, P11, DOI 10.3389/neuro.07.011.2007; Takahashi Yuji, 2008, Front Neurosci, V2, P86, DOI 10.3389/neuro.01.014.2008; Thanos PK, 2001, J NEUROCHEM, V78, P1094, DOI 10.1046/j.1471-4159.2001.00492.x; van der Meer Matthijs A A, 2009, Front Integr Neurosci, V3, P1, DOI [10.3389/neuro.07.001.2009, 10.3389/neuro.07.009.2009]; Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05-2005; Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975; Volkow ND, 1999, AM J PSYCHIAT, V156, P1440; Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452; Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006; Volkow ND, 2008, PHILOS T R SOC B, V363, P3191, DOI 10.1098/rstb.2008.0107; Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507; Volkow ND, 2006, ARCH GEN PSYCHIAT, V63, P999, DOI 10.1001/archpsyc.63.9.999; Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194; Zangen A, 2002, J NEUROSCI, V22, P7225; Zangen A, 2006, J NEUROSCI, V26, P4901, DOI 10.1523/JNEUROSCI.3554-05.2006; Zhang J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000437
Number of Citaion: 143
Publication: M I T PRESS
City of Publication: CAMBRIDGE
Address of Publication: 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA
ISSN: 0899-7667
29-Character Source Abbreviation: NEURAL COMPUT
ISO Source Abbreviation: Neural Comput.
Volume: 22
Version: 9
Start of File: 2334
End of File: 2368
DOI: 10.1162/NECO_a_00009
Number of Pages: 35
Web of Science Category: Computer Science, Artificial Intelligence; Neurosciences
Subject Category: Computer Science; Neurosciences & Neurology
Document Delivery Number: 634EX
Unique Article Identifier: WOS:000280563600004
[이 게시물은 HyeJung Mo…님에 의해 2015-05-20 14:52:59 GAMBLING에서 이동 됨]
- reply : 0
-
- list
-
- prev
- next